The deal with China’s CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of ...

The drug licensing talks cover the development, production and sale of a targeted cancer therapy and other CSPC Pharma ...

13/06/2025 13:27 {Hot Stocks}CSPC PHARMA(01093) quoted at HK$8.59, down 5.1% 13/06/2025 10:07 {Hot Stocks}CSPC PHARMA(01093) quoted at HK$8.78, down 3% 12/06/2025 13:18 {Hot Stocks}2 listed firms see ...

AstraZeneca (AZ) and CSPC Pharmaceuticals Group have entered into a partnership worth up to $5.3bn to develop therapies for ...

Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 ...

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising ...

The collaboration aims to advance the discovery and development of novel oral candidates.

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

The collaboration will focus on identifying pre-clinical candidates for high-priority targets, including a small molecule ...

Cambridge: AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group ...

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.